Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 17/20 | 0.87 |
| ▸ | HTR1A | P08908 | 16/20 | 0.87 |
| ▸ | HTR1D | P28221 | 14/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.87 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.85 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL8628241 | 1.00 | HTR1B (0.87) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8631086 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402426 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8628236 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402421 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907322 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8624139 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907348 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907353 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907325 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | PALOMO LIMITED (CY) | 2015-11-05 | — | — | US | claimed |
| EP-2911697-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | Nlife Therapeutics S.L. (ES) | 2015-09-02 | — | — | EP | claimed |
| WO-2014064258-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | NLIFE THERAPEUTICS, S.L. (ES) | 2014-05-01 | — | — | WO | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2023-10-12 | — | — | US | disclosed |
| EP-4171545-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR) | 2023-05-03 | — | — | EP | disclosed |
| CN-115698321-A | Methods for plasma free RNA analysis | 格里尔公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3484462-B1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR SKIN AND/OR HAIR REPAIR | PASTEUR INSTITUT (FR) | 2022-12-14 | — | — | EP | disclosed |
| US-20220347127-A1 | USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11344515-B2 | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation | INSTITUT PASTEUR (FR) | 2022-05-31 | — | — | US | disclosed |
| EP-3377051-B1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL | PASTEUR INSTITUT (FR) | 2022-03-30 | — | — | EP | disclosed |
| US-7013836-B1 | Enhancing maturation of oocytes in bivalves | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2006-03-21 | — | — | US | disclosed |
| US-6787125-B1 | DISPENSING NEMATODE WORMS INTO MULTI-WELL PLATE CONTAINING CARBOXYMETHYL CELLULOSE; CONTACTING WITH CHEMICAL; DETECTING A SIGNAL INDICATING CHANGES; DRUG SCREENING; HIGH THROUGHPUT ASSAY | DEVGEN NV (BE) | 2004-09-07 | — | — | US | disclosed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-0666847-B1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMA (CA) | 1998-06-17 | — | — | EP | disclosed |
| US-5496957-A | 5-HYDOXYTRYPTAMINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0666847-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | Allelix Biopharmaceuticals Inc. (CA) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995006638-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | MSR1, HAVCR2, SNRPE | HTR1B 3994/4885HTR1A 4213/4885HTR1D 4705/4885 |
| US-11344515-B2 | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation | CHRNB1, HTR1B, CHRNB2 | HTR1B 2/4885HTR1A 5/4885HTR1D 40/4885 |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | SMPD2, SMPD1, SMPD3 | HTR1B 1264/4885HTR1A 676/4885HTR1D 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.